Anti-cancer agent comprising HVJ-E and CXCL2
AssigneesOsaka University, Genomidea Inc.
InventorsYasufumi Kaneda, Toshihiro Nakajima
Life of this patent
Estimating the term…
Abstract
The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
Claims12
A method for the prophylaxis or treatment of cancer, comprising administering an effective amount of a pharmaceutical composition comprising the following (1) and (2) to a subject:
- (1) HVJ-E (hemagglutinating virus of Japan envelope),
- (2) CXCL2 or a nucleic acid comprising a base sequence encoding CXCL2.
A method of inducing an N1 type neutrophil, comprising administering an effective amount a pharmaceutical composition comprising the following (1) and (2) to a subject:
- (1) HVJ-E (hemagglutinating virus of Japan envelope),
- (2) CXCL2 or a nucleic acid comprising a base sequence encoding CXCL2.
Dependencies are inferred from the claim text.